However, the expression level of EGFR on tumour cells per se, as determined by immunohistochemistry, was not predictive of therapeutic response in gastric and OGJ cancer in various phase II trials of cetuximab in combination with chemotherapeutic agents [8,10,25]. The gene discussed is EGFR; the disease is neoplasm.